Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-001 for Hair Shedding Reduction and Hair Re-Growth
NCT06648850Phase 3Not yet recruiting
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of DA-001 in telogen effluvium (TE), androgenetic alopecia (AGA). Planned start May 2026; status: not yet recruiting.
02
Drugs
DA-001
03
Conditions
telogen effluvium (TE)androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT06648850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06648850.